stonks4u
Sign up free
INDP logo

INDP Indaptus Therapeutics, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$1.07
+0.01 (+0.94%)

Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic r…

Market Cap: $121.17Mindaptusrx.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 13Aug 13

Quote

Day Range
$1.04 – $1.15
52-Week Range
$0.92 – $8.57
Volume
$130.8K
Market Cap
$121.17M
50-Day Avg
$2.54
200-Day Avg
$2.32
Prev Close
$1.06
Open
$1.09

Valuation & Ratios

P/E Ratio
-0.13
EPS
$-21.58
P/B Ratio
0.89
P/S Ratio
0.00
Debt/Equity
0.00
Current Ratio
1.51
Dividend Yield
+0.0%
Gross Margin
+0.0%

Returns & Efficiency

Return on Equity
-661.5%
Return on Assets
-223.9%
FCF Yield
-527.3%
EV/EBITDA
0.27

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$0.00$-20.85M$-21.58
2024$0.00$-15.02M$-1.61
2023$0.00$-15.42M$-1.84
2022$0.00$-14.32M$-1.73
2021$0.00$-7.71M$-1.89

Social Signal Score

50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Tue, Nov 17(in 3 months)

Consensus estimate $-1.46 per share

7of 7 quarters beat consensus

Typical surprise +28.5% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$-0.02 vs $-1.57beat
  • Fri, May 15$-0.23 vs $-1.87beat
  • Tue, Mar 17$-3.10 vs $-4.36beat
  • Wed, Nov 12$-2.98 vs $-4.17beat
  • Wed, Aug 13$-9.09 vs $-9.24beat
  • Wed, May 14$-8.96 vs $-11.48beat

Estimates and results for INDP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

INDPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·2d ago·Neutral

    Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced financial results for the second quarter and six months ended June 30, 2026, and provided a corporate update.

    View source ↗